Lebanon, NHNCT05933395Now EnrollingIRB Ready

Advanced Breast Cancer Clinical Trial in Lebanon, NH

Access cutting-edge advanced breast cancer treatment through this clinical trial at a research site in Lebanon. Study-provided care at no cost to qualified participants.

Sponsored by Dartmouth-Hitchcock Medical Center

Quick Self-Assessment

See if you qualify for this Lebanon location

Preparing your pre-screening questions…

Expert Care in Lebanon

Access advanced breast cancer specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related advanced breast cancer treatment provided free

Apply for This Lebanon Location

Check if you qualify for this advanced breast cancer clinical trial in Lebanon, NH

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Lebanon

    Convenient for NH residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Lebanon site if eligible
  4. 4Begin participation

About This Advanced Breast Cancer Study in Lebanon

The purpose of this study is to learn if certain drug combinations are effective treatments for patients with advanced ER+/HER2- who have previously been treated with palbociclib, ribociclib, or abemaciclib.

Sponsor: Dartmouth-Hitchcock Medical Center

Who Can Participate

Inclusion Criteria

Post-menopausal women ≥18 years of age with metastatic ER+ breast cancer, or with locally recurrent ER+ disease not amenable to therapy for curative intent.
Patient must be post-menopausal per NCCN guidelines.
Patient must have been treated with a CDK4/6i (either palbobclib, ribociclib, or abemaciclib) alone or in combination with an endocrine agent in the advanced disease setting.
Up to 3 lines of therapy following CDK4/6i are permissible.
Any number of prior lines of endocrine-containing therapy is permissible.
Up to 1 prior line of chemotherapy is permissible.
Histologic documentation of ER+ breast cancer by core needle biopsy, fine needle aspiration, incisional biopsy, or surgical biopsy of ≥1 site(s) of metastatic or locally recurrent disease performed as standard of care.
Exceptions: patients with bone-dominant metastatic disease, or non-bone metastatic disease in whom a safe and accurate biopsy of recurrent/metastatic disease cannot be readily obtained, with a history of ER+ breast cancer are eligible, and biopsy is not required, providing their primary cancer is consistent with the ER criteria described below.
ER+ status defined as ER staining by immunohistochemistry in ≥1% of malignant cell nuclei.
Tumor must be HER2-non-amplified as defined by an immunohistochemistry score of 0-1+, or with a FISH ratio \<2 if IHC is 2+ or if IHC has not been done (as per ASCO/CAP definitions). In cases of borderline or equivocal HER2 status, eligibility will be determined by the PI.
Genetic profiling of a tumor or plasma specimen acquired after disease progression on a CDK4/6i must have been performed in a CAP-accredited, CLIA-certified laboratory using clinically validated methods. Profiling must minimally include analysis of study-relevant alterations in ERBB2, PIK3CA, AKT1, MTOR, PTEN, and RB1.
If not done: Profiling of a tumor (preferable) or plasma specimen will be performed as part of the study in the DHMC Pathology Laboratory. A plasma specimen may be obtained for study-specific genetic profiling to direct treatment assignment. Tumor specimens must be obtained outside of this study (e.g., by biopsy).
If available, archived tumor tissue must be accessible for research purposes, sufficient to make ≥10 five-micron sections; more tumor tissue is preferred.
Radiographic staging performed as standard of care, including specifically either PET/CT, or contrast CT (CAP) and bone scan.
Patient must be capable and willing to provide informed written consent for study participation.

Exclusion Criteria

Treatment with abemaciclib in the most recent or current line of therapy.
During the study Treatment Phases, no concurrent anti-cancer therapies are allowed with the following exception: anti-resorptive bone therapies (e.g., bisphosphonates, denosumab) are permitted.
Any investigational cancer therapy in the last 3 weeks.
Known untreated CNS disease, unless clinically stable for ≥ 3 months.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Lebanon?

Yes, this clinical trial (NCT05933395) has an active research site in Lebanon, NH that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Advanced Breast Cancer Treatment Options in Lebanon, NH

If you're searching for advanced breast cancer treatment options in Lebanon, NH, this clinical trial (NCT05933395) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Lebanon research site is actively enrolling participants for this clinical trial. You'll receive care from experienced advanced breast cancer specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all advanced breast cancer clinical trials near you to find additional studies recruiting in your area.

More Breast Cancer Trials in Lebanon, NH

See all breast cancer clinical trials recruiting in Lebanon — not just this study.

Browse Breast Cancer Trials in Lebanon →

Browse More Trials by Condition

Breast Cancer TrialsAlzheimers Disease TrialsAnkylosing Spondylitis TrialsAtopic Dermatitis TrialsErectile Dysfunction TrialsAll Conditions →

Ready to Join in Lebanon?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Lebanon, NH